Jaguar Health Files Proxy Materials

TL;DR

Jaguar Health filed proxy docs, no fee needed.

AI Summary

Jaguar Health, Inc. filed a Definitive Additional Materials (DEFA14A) on August 6, 2025. This filing is related to their proxy statement and indicates no fee was required for this filing. The company, formerly known as Jaguar Animal Health, Inc., is based in San Francisco, CA.

Why It Matters

This filing is a routine regulatory submission for Jaguar Health, Inc., providing updated information to shareholders regarding proxy matters.

Risk Assessment

Risk Level: low — This filing is a standard regulatory disclosure and does not present immediate financial risk.

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant
• Jaguar Animal Health, Inc. (company) — Former company name
• 200 PINE STREET SUITE 400 (address) — Business and Mail Address
• SAN FRANCISCO (location) — City
• CA (location) — State
• 94104 (zip_code) — Zip Code
• 415-371-8300 (phone_number) — Business Phone
• 0001193125-25-174505 (filing_id) — Accession Number
• 20250806 (date) — Filing Date

FAQ

From the Filing

0001193125-25-174505.txt : 20250806 0001193125-25-174505.hdr.sgml : 20250806 20250806163115 ACCESSION NUMBER: 0001193125-25-174505 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20250806 DATE AS OF CHANGE: 20250806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 251190154 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 DEFA14A 1 d929413ddefa14a.htm DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 JAGUAR HEALTH, INC. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. JAGUAR HEALTH, INC. SUPPLEMENT TO THE DEFINITIVE PROXY STATEMENT DATED JULY 21, 2025 FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON TUESDAY, AUGUST 19, 2025 This supplement (this “Supplement”) amends and supplements the proxy statement of Jaguar Health, Inc. (the “Company”), dated July 21, 2025 (the “Proxy Statement”), filed with the U.S. Securities and Exchange Commission in connection with the Company’s 2025 Annual Meeting of Stockholders to be held on August 19, 2025 (the “Annual Meeting”). Pursuant to the rules of The New York Stock Exchange (“NYSE”), Proposal 7 in the Proxy Statement (a proposal to grant discretionary authority for the Company to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve Proposals 3, 4, 5 and 6) is a “ non-routine ” matter. Therefore, brokerage firms may not vote uninstructed shares regarding Proposal 7. Except as specifically supplemented by the information contained herein, all information set forth in the Proxy Statement remains unchanged. From and after the date of this Supplement, all references to the “Proxy Statement” are to the Proxy Statement as supplemented this Supplement. The Proxy Statement contains important information and this Supplement should be read in conjunction with the Proxy Statement. The Proxy Statement previously advised stockholders that Proposal 7 is a discretionary or “routine” matter. In accordance with the supplemented information above, the following disclosures under the heading “Broker Voting” contained in the Proxy Statement are hereby amended and restated in their entirety to read as follows: Broker Voting Brokers holding shares of record in “street name” for a beneficial owner have the discretionary authority to vote on some matters (routine matters) if they do not receive instruction